Welcome and introductions – Plenary

Technical Break

Topic 1.1 Biology of precursor CLL and FL conditions

Moderators: Sandrine Roulland

• Genomic sequencing in MBL: Susan Slager
  • Germline risk determination for progression from MBL (-low to -high), including intra-patient changes in their clonal genetic profile in MBL-low
  • Familial MBL-CLL and implications for risk of MBL progression
• Early FL precursors: in-situ follicular neoplasia and follicular lymphoma-like cells: Sandrine Roulland

Panel discussion – all speakers

Topic 1.2: The role of MBL in the etiology of CLL   

Moderators: Tait Shanafelt

• Low- and high-count MBL: Prevalence and consequences: Andrew Rawstron
  • How to differentiate:
    • clinical consequences of low-/high-count MBL assessment
    • Low-count MBL in African versus European/North American MBL populations
• Impact of CLL cell surface IgM levels on disease progression and escape of BTK inhibition: Francesco Forconi

Panel discussion – all speakers

Topic 1.3: Precursor conditions in Waldenström Macroglobulinemia

Moderators: Paolo Ghia

• Pre-neoplastic somatic mutations and malignant transformation of Waldenström Macroglobulinemia: Bruno Paiva
• CBL-MZ; precursor of SMZL: Kostas Stamatopoulos
  

Panel discussion – all speakers

Welcome reception/buffet 

Welcome and outline of the day (plenary): Irene Ghobrial and Jesús San-Miguel

Technical break

Session 2: A focus on the indolent-to-aggressive transition in blood cancers

Topic 2.1: Overview of progression in MBL

Moderators: Paolo Ghia

• Early/highly sensitive detection of MBL: Julia Almeida
• The BCR repertoire in MBL vs CLL: role in disease progression: Kostas Stamatopoulos
• Immune dysregulation in MBL (potential for inclusion of data on the frequency of MBL in patients with COVID-19): Alberto Órfão

Panel discussion – all attendees

Break 

Topic 2.2: Indolent to aggressive: Progression of CLL and FL

Moderators: Tait Shanafelt

• Technologies for detecting progression: Single-cell analysis technologies in CLL: Giovanni Tonon
• Early detection of risk-of-progression of CLL to Richter syndrome: Iñaki Martín-Subero
• Role of the microenvironment in FL pathogenesis and progression: TBC
• Progression of indolent FL to aggressive lymphomas: Miguel Alcoceba

Panel discussion – all speakers

Session 3: Opportunities for therapeutic intervention in early CLL

Topic 3.1: Overview of ongoing clinical studies and preliminary data

Moderators: Matthew Davids 

• Ibrutinib in a patient population who would otherwise not meet the inclusion criteria for existing CLL clinical trials – trial overview and preliminary data: Petra Langerbeins
• Preliminary data from the NeoVax CLL study in patients otherwise excluded from clinical trials in CLL – development of a personalized vaccine: Inhye Ahn
• Venetoclax + obinutuzumab in early high-risk CLL: early versus later treatment initiation – study design ahead of anticipated data: Deborah Stephens

Panel discussion – all speakers

Lunch break

Keynote: FDA presentation (plenary session): Nicole Gormley

Technical break

Session 4: T-cell clones of uncertain significance (TCUS)

Topic 4.1: TCUS and T-cell LGL leukemia – laboratory diagnostics

Moderators: Alberto Órfão

• TCUS and T-cell LGL leukemia – implications for laboratory diagnostics: Julia Almeida
• STAT-pathway mutations in the pathogenesis of T-LGL leukemia: Thomas Loughran
• Morphologic, immunophenotypic and molecular features of T-LGL leukemia – therapeutic implications: Gianpietro Semenzato

Panel discussion – all speakers

Technical break

Roundtable discussion – myeloma, CHIP/CCUS, MBL-CLL and lymphomas

Moderators: Matthew Davids, Kenneth Anderson and George Vassiliou

• Populations at risk for progression and concepts of interception
• Current end points of clinical trials in early interception in CCU and CLL, and where to go from there
• Should we be screening for CHIP, MBL, MGUS, and who to screen?

Group photo

Faculty dinner

Plenary: Presentation of key points – sharing from each disease track

Panel discussion

Thematic discussions

Summary conclusions and end of meeting: Irene Ghobrial and Jesús San-Miguel

END

Welcome and introductions – Plenary

Technical Break

Session 1: Mechanisms of clonal expansion and transformation

Topic 1.1 Genomics/observational

Moderators: George Vassiliou and Siddhartha Jaiswal

• Natural History/dynamics: George Vassiliou
• Genetic predisposition: Siddhartha Kar
• Ageing and clonal expansion rate: Alexander Bick
• Copy number: Jamie Blundell

Panel discussion – all speakers

Topic 1.2: Molecular mechanisms

Moderators: George Vassiliou and Siddhartha Jaiswal

• Implications of germline TCL1A variants: Siddhartha Jaiswal
• Myeloid/lymphoid somatic gene mutations and risk of hematologic malignancy: Lachelle Weeks
• Acquisition of driver mutations in DNM3TA as a precursor to CH: Elisa Laurenti
• Driver mutations in DNM3TA or implications of PPM1D clonal mutations: Liran Shlush

Panel discussion – all speakers

Welcome reception/buffet 

Welcome and outline of the day (plenary): Irene Ghobrial and Jesús San-Miguel

Technical break

Session 2: Risk factors and predictive modelling

Topic 2.1: Prediction of adverse outcomes

Moderators: Luca Malcovati

• Predictive models – Lesson from population-based studies: Lachelle Weeks
• Context-dependent risk factors – CH and exposure to genotoxic agents: Kelly Bolton

Panel discussion – all attendees

Break

Topic 2.2: Clonal hematopoiesis in the clinics

Moderators: Lambert Busque and Felipe Prósper

• CHIP, CCUS and early MDS – clinical classification and predictive models: Luca Malcovati
• CHIP clinic: who, when, how?: Eric Padron
• CHIP and genetic predisposition: Lucy Godley

Panel discussion – all speakers

Session 3: Early intervention

Topic 3.1: Pre-clinical

Moderators: Kelly Bolton

• Epigenetic studies: John Pimanda
• Mechanisms of immune evasion in myeloid malignancies: Iannis Aifantis
• Pre-clinical studies targeting clonal hematopoiesis HSPCs: Ravi Majeti
• RNA splicing: Omar Abdel-Wahab

Panel discussion – all speakers

Lunch break

Keynote: FDA presentation (plenary session): Nicole Gormley

Technical break

Topic 3.2: Clinical

Moderators: Kelly Bolton and Kirsten Grønbaek

• Vitamin C: Mrinal Patnaik
• Oral vitamin C and Metformin in CCUS: Kirsten Grønbaek
• Anti-IL1: Uma Borate

Panel discussion – all speakers

Technical break

Roundtable discussion – Myeloma, CHIP/CCUS, MBL-CLL and lymphomas

Moderators: Matthew Davids, Kenneth Anderson and George Vassiliou

• Populations at risk for progression and concepts of interception
• Current end points of clinical trials in early interception in CCU and CLL, and where to go from there
• Should we be screening for CHIP, MBL, MGUS, and who to screen?

Group photo

Faculty dinner

Plenary: Presentation of key points – sharing from each disease track

Panel discussion

Thematic discussions

Summary conclusions and end of meeting: Irene Ghobrial and Jesús San-Miguel

END

Welcome and introductions – Plenary

Technical Break

Session 1: Uncovering mechanisms of transformation

Keynote: The interplay between genes and the immune system: Kenneth Anderson

Topic 1.1 Genomics of MGUS and SMM

Moderators: Gareth Morgan

• Genomics of transformation: Francesco Maura
• Epigenetics of transformation: Felipe Prósper
• Molecular classification of SMM: Irene Ghobrial

Panel discussion – all speakers

Topic 1.2: Animal models to study disease progression

Moderators: Leif Bergsagel and Irene Ghobrial

• Immune recapitulation: Madhav Dhodapkar
• Genetic transition under immunocompetence: José Ángel Martínez Climent
• In vivo model systems and the interaction between clonal hematopoiesis and plasma cell neoplasms: Adam Sperling

Panel discussion – all speakers

Topic 1.3: Immune microenvironment of MGUS and smoldering myeloma

Moderators: Kenneth Anderson and Bruno Paiva

• Early immune derailment: Gad Getz
• Immune biomarkers of response to therapy, immune MRD: Romanos Sklavenitis-Pistofidis
• Metabolomics and the immune system: Urvi Shah

Panel discussion – all speakers

Welcome reception/buffet 

Welcome and outline of the day (plenary): Irene Ghobrial and Jesús San-Miguel

Technical break

Session 2: Risk factors and risk models for progression

Topic 2.1: MGUS/SMM screening and risk

Moderators: Rafael Fonseca and María-Victoria Mateos

• Natural history of MGUS: Rafael Fonseca
• iStopMM: Sigurður Kristinsson
• African Americans and family studies perspective including the PROMISE study: Catherine Marinac
•  Is MGUS a benign disease? MGUS of clinical significance (MGRS, Neuropathy): Angela Dispenzieri
  
  Panel discussion – all speakers

Break 

Topic 2.2: Risk factors and classification in SMM 

Moderators: Meletios Dimopoulos and Shaji Kumar

• Progress from the 20/20/20 classification: Elizabeth O’Donnell
• Immune biomarkers and circulating tumor cells: Bruno Paiva
• Clinical and bone biomarkers including the PANGEA model: Efstathios Kastritis
• Biomarkers to predict risk of AL amyloidosis: Mario Nuvolone

Panel discussion – all speakers

Section 3: Is it the right time for early treatment intervention?

Topic 3.1: Clinical trials

Moderators: Jesús San-Miguel

• Phase 2 trials: Shaji Kumar
• Phase 3 trials: María-Victoria Mateos
• Novel drugs and combinations: Salomon Manier
• Trials in immunotherapy: Omar Nadeem

Panel discussion – all speakers

Lunch break

Keynote: FDA presentation (plenary session): Nicole Gormley

Technical break

Topic 3.2: Roundtable discussion on smoldering myeloma

Moderators: Kenneth Anderson

• This is a round table discussion that will include the FDA, biotech, academia and foundations.
  Topics that will be discussed:
  – Inclusion criteria
  – Duration of therapy
  – Primary endpoints
  – Progression post-therapy in SMM
  – Access to clinical trials
  – Quality of life measures

Technical break

Roundtable discussion – myeloma, CHIP/CCUS, MBL-CLL and lymphomas

Moderators: Matthew Davids, Kenneth Anderson and George Vassiliou

• Populations at risk for progression and concepts of interception
• Current end points of clinical trials in early interception in CCU and CLL, and where to go from there
• Should we be screening for CHIP, MBL, MGUS, and who to screen?

Group photo

Faculty dinner 

Plenary: Presentation of key points – sharing from each disease track

Panel discussion

Thematic discussions

Summary conclusions and end of meeting: Irene Ghobrial and Jesús San-Miguel

END